Healthy AdultDNF10-APETNCT07621393
Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10
A study testing DNF-10: 500 mg/day in people with Healthy Adult, run by Fytexia at 1 site in Spain.
Trial summary
This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg/m². Read more about this study
- Who is it for?
- Ages 20 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult
- What is being tested?
- DNF-10: 500 mg/day
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteSpain
- Study dates
- 12 May 2026to Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy men and women aged 20 to 50 years.
- Body Mass Index (BMI) of 18.5-24.9 kg/m² or 25.0-29.9 kg/m².
- Stable use of permitted medications and/or dietary supplements during the study.
- Individuals willing to maintain their usual dietary and physical activity habits throughout the study.
- Subjects capable of understanding and complying with the study procedures.
- Subjects who have signed the informed consent form.
Show all 9Show fewer
- Female participants must meet one of the following conditions:
- Women with no potential for pregnancy, defined as women who have undergone surgical sterilization or who are postmenopausal.
- Women of childbearing potential who use a highly effective contraceptive method (hormonal contraception, intrauterine device, condoms, male partner sterilization [vasectomy], or complete sexual abstinence) while participating in the study.
Who cannot join
- Individuals with known eating behavior disorders (verified using the Spanish version of the Adult Eating Behavior Questionnaire, AEBQ).
- Subjects with a body weight gain or loss ≥10% within the previous 3 months.
- Treatment with medications or dietary supplements for weight loss, satiety, or glucose control.
- Individuals consuming protein powders or dietary supplements related to the objectives of the study.
- Participants receiving active treatment with GLP-1 receptor agonists or similar agents.
- Participants taking medications or dietary supplements that, in the investigator's opinion, may interfere with the study objectives (e.g., affecting appetite), pose a safety risk, or confound the interpretation of the study results.
Show all 20Show fewer
- Depression or anxiety disorders that affect appetite.
- High coffee consumption (more than 4 cups per day).
- Smokers (more than 5 cigarettes per week), smoking during study assessment days, and/or drug abuse.
- History of bariatric surgery within the last 3 years.
- Low iron levels requiring treatment.
- Individuals with renal or endocrine diseases (including diabetes).
- Untreated or unstable hyperthyroidism, suicidal ideation, bipolar disorder, or evidence of any untreated or unstable neurological disorder.
- Conditions or diseases that, in the investigator's judgment, may be worsened by participation in the study or may jeopardize the conduct of the study.
- Presence of infectious diseases at the time of study inclusion (participants may be included 1 month after resolution of the illness).
- Severely immunocompromised participants (transplant recipients, individuals treated with anti-rejection medications or steroids within the previous 30 days, or those who have received chemotherapy or radiotherapy within the last year).
- Presence of active malignancy or any concomitant end-stage organ disease within the last 12 months that, in the investigator's judgment, contraindicates participation in the study.
- Hypersensitivity, allergy, or intolerance to any of the components of the study product or standardized study menus (e.g., cow's milk protein allergy [CMPA], celiac disease, or non-celiac gluten intolerance).
- Current participation or participation in another clinical trial within the previous three months.
- Pregnant or breastfeeding women, women seeking pregnancy, or women of childbearing potential who are unwilling to use an effective contraceptive method.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Hospital Universitario HM Sanchinarro
Madrid, 28050
Ismael San Mauro Martín Dr., +34617765977, info@grupocinusa.es
Domingo Carrera
About this study
Official title: Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10: Pilot Proof-of-concept, Crossover, Exploratory, Randomized, Double-blind, Placebo-controlled Study
This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg/m². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.
- Conditions
- Healthy Adult
- Being tested
- DNF-10: 500 mg/day, Placebo: 500 mg maltodextrin/day
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DNF-10: 500 mg/dayDietary supplement
DNF-10
Placebo: 500 mg maltodextrin/dayOther
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | DNF-10 Receives: Dietary Supplement: DNF-10: 500 mg/day |
| Control | Placebo comparator | Placebo Receives: Other: Placebo: 500 mg maltodextrin/day |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with dysfunctional eating behavior
The primary objective of the study is to evaluate the effect of DNF-10 on dysfunctional eating behavior in the study population compared with placebo, specifically on the frequency of:
- unplanned eating episodes (snacking),
- levels of food-related anxiety, and
- the expression of emotional hunge.
Measured: Baseline and after 1 month of treatment in each treatment period
Secondary outcomes (4)
Amount of food intake in response to emotional states
Measured: Baseline and after 1 month of treatment in each treatment period
Concentration of entero-hormone biomarkers
Measured: Baseline and after 1 month of treatment in each treatment period
Weight in kilograms
Measured: Baseline and after 1 month of treatment in each treatment period
Waist circumference in centimeters
Measured: Baseline and after 1 month of treatment in each treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start12 May 2026
- Primary completionDec 2026 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fytexia
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Centros de Investigación de Nutrición y Salud
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07621393
- Sponsor's protocol ID
- DNF10-APET
- Acronym
- DNF10-APET
- Status last verified
- Oct 2026
- First submitted
- 14 Apr 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10: Pilot Proof-of-concept, Crossover, Exploratory, Randomized, Double-blind, Placebo-controlled Study
- ClinicalTrials.gov ID
- NCT07621393
- Acronym / sponsor ID
- DNF10-APET / DNF10-APET
- Conditions
- Healthy Adult
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- FytexiaIndustry (pharma, biotech, devices)
- Collaborators
- Centros de Investigación de Nutrición y Salud
- Study start
- 12 May 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg/m². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Dietary Supplement: DNF-10: 500 mg/dayDNF-10 |
| Control | Placebo comparator | Other: Placebo: 500 mg maltodextrin/dayPlacebo |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Healthy men and women aged 20 to 50 years.
- Body Mass Index (BMI) of 18.5-24.9 kg/m² or 25.0-29.9 kg/m².
- Stable use of permitted medications and/or dietary supplements during the study.
- Individuals willing to maintain their usual dietary and physical activity habits throughout the study.
- Subjects capable of understanding and complying with the study procedures.
Key exclusion criteria (20 listed)
- Individuals with known eating behavior disorders (verified using the Spanish version of the Adult Eating Behavior Questionnaire, AEBQ).
- Subjects with a body weight gain or loss ≥10% within the previous 3 months.
- Treatment with medications or dietary supplements for weight loss, satiety, or glucose control.
- Individuals consuming protein powders or dietary supplements related to the objectives of the study.
- Participants receiving active treatment with GLP-1 receptor agonists or similar agents.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DNF-10: 500 mg/dayDNF-10 | Dietary supplement | Experimental |
| Placebo: 500 mg maltodextrin/dayPlacebo | Other | Control |
Primary outcome
Number of Participants with dysfunctional eating behavior
Time frame: Baseline and after 1 month of treatment in each treatment period
The primary objective of the study is to evaluate the effect of DNF-10 on dysfunctional eating behavior in the study population compared with placebo, specifically on the frequency of: * unplanned eating episodes (snacking), * levels of food-related anxiety, and * the expression of emotional hunge.
4 secondary outcomes
Amount of food intake in response to emotional states
Time frame: Baseline and after 1 month of treatment in each treatment period
Concentration of entero-hormone biomarkers
Time frame: Baseline and after 1 month of treatment in each treatment period
Weight in kilograms
Time frame: Baseline and after 1 month of treatment in each treatment period
Waist circumference in centimeters
Time frame: Baseline and after 1 month of treatment in each treatment period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Adult
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DNF-10: 500 mg/day in people with Healthy Adult, run by Fytexia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with dysfunctional eating behavior (time frame: Baseline and after 1 month of treatment in each treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.